Weight and cardiovascular outcomes: different objectives
The outcome's definition determines what we can say about a finding.
STEP 1 as an example of a weight-focused trial.
The outcome's definition determines what we can say about a finding.
What was studied
STEP 1 enrolled 1,961 adults without diabetes and compared weekly subcutaneous semaglutide with placebo over 68 weeks, both alongside a lifestyle intervention. Mean weight change was −14.9% versus −2.4%. Discontinuations for gastrointestinal events were 4.5% versus 0.8%. Funding: Novo Nordisk.
Reading with context intact
The mean does not predict every participant's change. This weight trial does not replace a study primarily designed to prevent cardiovascular events. Comparing their questions is educational; it does not rank treatments using percentages from separate studies.
Professional context / Contexto profesional
Retain the full eligibility criteria: BMI ≥30, or ≥27 with at least one weight-related condition; no diabetes. The research intervention included escalation to 2.4 mg weekly. This description is not an individual regimen.
Evidence / Evidencia
Randomized, double-blind, placebo-controlled trial; published in 2021.
Limitations / Limitaciones
Brief summary, not an exhaustive evaluation of efficacy, safety or current indications.